ReviewCurrent allergy and asthma reports2026
A Parade of Persistent and Emerging Contact Allergens - A Clinical Update.
Review in Current allergy and asthma reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewClinical management of allergic contact dermatitis (ACD) is increasingly challenging due to the growing number of allergens, complex exposure patterns, and evolving regulatory frameworks. This review aims to provide clinicians with an updated overview of well-known as well as new and emerging allergens relevant to the diagnosis and management of ACD. RECENT
findingsRecent literature highlights changing exposure patterns and the identification of several new and emerging allergens, particularly in rapidly expanding consumer markets such as cosmetics and products associated with medical devices. In addition, updated evidence has refined the clinical relevance of established allergen groups, including fragrances, metals, rubber chemicals, acrylates, and preservatives. Post-marketing surveillance of products and clinical patch test data continue to play an important role in detecting novel sensitizers and shifting exposure scenarios. Clinicians must remain vigilant, as exposure patterns continue to evolve with the introduction of new ingredients and products while established allergens persist. Ongoing surveillance and updated clinical awareness are essential to ensure accurate diagnosis and prevention of ACD.
Indexed as
Identifiers
41920264What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.